{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:44:25Z","timestamp":1770835465373,"version":"3.50.1"},"reference-count":33,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin's lymphoma that represents a heterogeneous group of disease that is differentially characterised by clinical, molecular and cytogenetic features.\n                      <jats:italic>MYC<\/jats:italic>\n                      ,\n                      <jats:italic>BCL2<\/jats:italic>\n                      and\n                      <jats:italic>BCL6<\/jats:italic>\n                      gene rearrangements have been identified as prognostic factors in DLBCL, especially for\n                      <jats:italic>MYC<\/jats:italic>\n                      . Nevertheless the frequency and effect of atypical\/unbalanced\n                      <jats:italic>BCL6, BCL2<\/jats:italic>\n                      and\n                      <jats:italic>MYC<\/jats:italic>\n                      translocations in DLBCL is not fully documented. Here, we aimed to analyse those atypical\/unbalanced rearrangements in DLBCL and to assess their prognostic impact.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We collected tumour tissue and clinical data from 97 DLBCL and used interphase fluorescence in situ hybridisation (FISH) with break-apart probe to characterise\n                      <jats:italic>BCL6, BCL2<\/jats:italic>\n                      and\n                      <jats:italic>MYC<\/jats:italic>\n                      gene pattern.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      19 of 97 (19,6%) cases of DLBCL had atypical\/ unbalanced gene rearrangements (14 involving\n                      <jats:italic>BCL6<\/jats:italic>\n                      gene, 5 involving\n                      <jats:italic>BCL2<\/jats:italic>\n                      gene and none involving\n                      <jats:italic>MYC<\/jats:italic>\n                      gene). Compared with patients with simple gene rearrangement and patients without cytogenetic abnormality, patients with atypical\/unbalanced gene rearrangement were in an unfavourable risk group by the International Prognostic Index (p=0039), died of disease (p=0012), harboured relapse or progression (p=0011) and had shorter overall (p=0,04), relapse free (p=0029) and event free (p=0026) survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We showed that patients with DLBCL with\n                      <jats:italic>BCL2<\/jats:italic>\n                      or\n                      <jats:italic>BCL6<\/jats:italic>\n                      atypical\/unbalanced rearrangements constituted a group of patients with poor outcome. We also underlined the importance of FISH analyses, easily feasible in routine practise, at diagnosis of DLBCL to detect the rather frequent and clinically significant atypical\/unbalanced aberrations of these genes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2020-206767","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:23:08Z","timestamp":1599758588000},"page":"650-656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["<i>BCL2<\/i>\n                    and\n                    <i>BCL6<\/i>\n                    atypical\/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course"],"prefix":"10.1136","volume":"74","author":[{"given":"Alicia","family":"Tourneret","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement de Pathologie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alame","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement d'Hematologie Biologique, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Rigau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement de Pathologie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Bauchet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement de Neurochirurgie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[{"name":"ICM Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"De Oliveira","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valere","family":"Cacheux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement d'Hematologie Biologique, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Costes","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement de Pathologie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-9910","authenticated-orcid":false,"given":"Vanessa","family":"Lacheretz-Szablewski","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montpellier, Montpellier, France"},{"name":"D\u00e9partement de Pathologie, CHU Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2025112110421796000_74.10.650.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . Who classification of tumours of haematopoietic and lymphoid tissues. 4th Edn. WHO Classification of Tumours, 2017."},{"key":"2025112110421796000_74.10.650.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"2025112110421796000_74.10.650.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"2025112110421796000_74.10.650.4","first-page":"3562","article-title":"The International prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the Parma trial. Parma group","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"2025112110421796000_74.10.650.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212191"},{"key":"2025112110421796000_74.10.650.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0985"},{"key":"2025112110421796000_74.10.650.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"2025112110421796000_74.10.650.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220095"},{"key":"2025112110421796000_74.10.650.9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066209"},{"key":"2025112110421796000_74.10.650.10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12212"},{"key":"2025112110421796000_74.10.650.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647602"},{"key":"2025112110421796000_74.10.650.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025112110421796000_74.10.650.13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.87"},{"key":"2025112110421796000_74.10.650.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0851"},{"key":"2025112110421796000_74.10.650.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"2025112110421796000_74.10.650.16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.223891"},{"key":"2025112110421796000_74.10.650.17","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/modpathol.2017.93","article-title":"Increased Myc copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma","volume":"30","author":"Quesada","year":"2017","journal-title":"Mod Pathol"},{"key":"2025112110421796000_74.10.650.18","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.18632\/oncotarget.4073","article-title":"Myc or Bcl2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"key":"2025112110421796000_74.10.650.19","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.065227"},{"key":"2025112110421796000_74.10.650.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.06.032"},{"key":"2025112110421796000_74.10.650.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7058"},{"key":"2025112110421796000_74.10.650.22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7150\/jca.36954","article-title":"C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases","volume":"11","author":"Salam","year":"2020","journal-title":"J Cancer"},{"key":"2025112110421796000_74.10.650.23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"Pd1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival","volume":"35","author":"Four","year":"2017","journal-title":"Hematol Oncol"},{"key":"2025112110421796000_74.10.650.24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00277-018-3498-z","article-title":"Myc, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type","volume":"98","author":"Nosrati","year":"2019","journal-title":"Ann Hematol"},{"key":"2025112110421796000_74.10.650.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-747022"},{"key":"2025112110421796000_74.10.650.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804295105"},{"key":"2025112110421796000_74.10.650.27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007203"},{"key":"2025112110421796000_74.10.650.28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03435.x"},{"key":"2025112110421796000_74.10.650.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03076.x"},{"key":"2025112110421796000_74.10.650.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435842"},{"key":"2025112110421796000_74.10.650.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63284-1"},{"key":"2025112110421796000_74.10.650.32","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","article-title":"Clinical relevance of BCL2, BCL6, and Myc rearrangements in diffuse large B-cell lymphoma","volume":"92","author":"Kramer","year":"1998","journal-title":"Blood"},{"key":"2025112110421796000_74.10.650.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.5897"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2020-206767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:42:26Z","timestamp":1763750546000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2020-206767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,9,20]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/jclinpath-2020-206767"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2020-206767","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}